Genovis AB (publ.) (STO:GENO)

Market Cap	1.35B -22.6%
Revenue (ttm)	131.09M +5.8%
Net Income	24.30M +2.8%
EPS	0.37 +2.1%
Shares Out	66.06M
PE Ratio	55.49
Forward PE	45.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,011
Open	20.50
Previous Close	20.80
Day's Range	20.20 - 21.20
52-Week Range	15.64 - 29.80
Beta	1.73
Analysts	Strong Buy
Price Target	32.67 (+59.76%)
Earnings Date	Jul 23, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 36
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2025, Genovis AB (publ.)'s revenue was 129.93 million, a decrease of -1.06% compared to the previous year's 131.32 million. Earnings were 23.50 million, a decrease of -28.61%.

Analyst Summary

According to 2 analysts, the average rating for GENO stock is "Strong Buy." The 12-month stock price target is kr 32.67, which is an increase of 59.76% from the latest price.

Price Target

kr 32.67

(59.76% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error